AIP
KROS icon

Ameritas Investment Partners’s Keros Therapeutics KROS Stock Holding History

Ameritas Investment Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.4K Hold
2,372
– – ﹤0.01% 2634
2026
Q1 		$26.2K Hold
2,372
– – ﹤0.01% 2470
2025
Q4 		$48.3K Sell
2,372
-515
-18% -$9.04K ﹤0.01% 2146
2025
Q3 		$45.7K Hold
2,887
– – ﹤0.01% 2196
2025
Q2 		$38.5K Hold
2,887
– – ﹤0.01% 2351
2025
Q1 		$29.4K Hold
2,887
– – ﹤0.01% 2388
2024
Q4 		$45.7K Hold
2,887
– – ﹤0.01% 2238
2024
Q3 		$168K Hold
2,887
– – 0.01% 1438
2024
Q2 		$132K Buy
2,887
+327
+13% +$17.6K ﹤0.01% 1552
2024
Q1 		$169K Buy
2,560
+324
+14% +$19.2K 0.01% 1403
2023
Q4 		$88.9K Hold
2,236
– – ﹤0.01% 1818
2023
Q3 		$71.3K Buy
2,236
+377
+20% +$14.1K ﹤0.01% 1878
2023
Q2 		$74.7K Buy
1,859
+448
+32% +$19.6K ﹤0.01% 1789
2023
Q1 		$60.3K Hold
1,411
– – ﹤0.01% 1855
2022
Q4 		$72.5K Hold
1,411
– – ﹤0.01% 1815
2022
Q3 		$53K Buy
1,411
+319
+29% +$11.1K ﹤0.01% 1938
2022
Q2 		$30K Hold
1,092
– – ﹤0.01% 2316
2022
Q1 		$59K Hold
1,092
– – ﹤0.01% 1962
2021
Q4 		$64K Hold
1,092
– – ﹤0.01% 1981
2021
Q3 		$43K Hold
1,092
– – ﹤0.01% 2261
2021
Q2 		$46K Hold
1,092
– – ﹤0.01% 2244
2021
Q1 		$67K Hold
1,092
– – ﹤0.01% 1905
2020
Q4 		$77K Buy
1,092
+477
+78% +$30.1K ﹤0.01% 1716
2020
Q3 		$24K Hold
615
– – ﹤0.01% 2286
2020
Q2 		$23K Buy
+615
New +$18.9K ﹤0.01% 2292

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Ameritas Investment Partners's KROS Position: Q2 2026 in Review

Ameritas Investment Partners held its Keros Therapeutics (KROS) position steady in Q2 2026 at 2,372 shares worth $25.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2634.

Ameritas Investment Partners first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $169K in Q1 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Ameritas Investment Partners held 2,372 shares of Keros Therapeutics worth $25.4K as of Q2 2026.
  • Ameritas Investment Partners left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2634 holding.
  • Ameritas Investment Partners first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Ameritas Investment Partners's Keros Therapeutics position peaked at $169K in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.